LAVAL, Quebec, May 19, 2015 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced the election of eleven directors nominated at its 2015 annual meeting of shareholders today. The detailed results of the vote for the election of directors are set out below: 



    Name          For             Withheld            Broker Non-Votes
    ----          ---             --------            ----------------


    Ronald H.
     Farmer           259,517,209           2,064,596               12,938,661

    Colleen A.
     Goggins          260,564,263           1,017,542               12,938,661

    Robert A.
     Ingram           258,725,145           2,856,660               12,938,661

    Anders Lönner     259,632,031           1,949,774               12,938,661

    Theo Melas-
     Kyriazi          260,811,015             770,790               12,938,661

    J. Michael
     Pearson          255,809,687           5,772,118               12,938,661

    Robert N.
     Power            258,849,981           2,731,824               12,938,661

    Norma A.
     Provencio        260,777,276             804,529               12,938,661

    Howard B.
     Schiller         250,437,448          11,144,357               12,938,661

    Katharine B.
     Stevenson        260,656,695             925,110               12,938,661

    Jeffrey W.
     Ubben            260,166,082           1,415,723               12,938,661

At the annual meeting, shareholders also approved the non-binding advisory vote on named executive officer compensation as disclosed in the proxy statement and appointed PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm until the close of the Company's 2016 annual meeting of shareholders.

The final vote tabulation on all matters voted on at today's meeting will be reported to the U.S. Securities and Exchange Commission on a current report on Form 8-K and such report will be made available on the Company's web site, www.valeant.com.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com

http://photos.prnewswire.com/prnvar/20101025/LA87217LOGO

Logo - http://photos.prnewswire.com/prnh/20101025/LA87217LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-announces-2015-annual-meeting-results-300085929.html

SOURCE Valeant Pharmaceuticals International, Inc.